NCT05824468 2026-03-10
Zimberelimab Plus Lenvatinib After Progression on Prior Immune Checkpoint Inhibitors for Advanced Cervical Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
Clinical Trials
12 trialsNCT05824481 2026-03-10
Study of Cadonilimab (AK104) Plus Lenvatinib in Patients With Advanced Endometrial Cancer
Sun Yat-sen University
Phase 2 Active not recruiting
NCT04318938 2026-03-02
Advancing Brigatinib Properties in ALK+ NSCLC Patients by Deep Phenotyping
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
Phase 2 Active not recruiting
NCT04440267 2025-08-06
Efficacy of Acute Lymphoblastic Leukemia-Based Therapy in Treating Patients With Acute Leukemia of Ambiguous Lineage
Institute of Hematology & Blood Diseases Hospital, China
Phase 2 Recruiting
NCT03314740 2025-01-10
BAROCCO
Mario Negri Institute for Pharmacological Research
Phase 2 Completed
NCT02949843 2024-06-28
Targeted Therapy in Treating Patients With Incurable Non-Small Cell Lung Cancer With Genetic Mutations
Wake Forest University Health Sciences
Phase 2 Terminated
NCT06232759 2024-06-10
TACE Combined With Tyrosine Kinase Inhibitors and Tislelizumab in Unresectable Hepatocellular Carcinoma
Guangxi Medical University
Phase 2 Completed
NCT06059885 2023-09-29
Tislelizumab Plus TKI as Adjuvant Therapy Versus Active Surveillance in Patients With HCC
Beijing 302 Hospital
Phase 2 Unknown
NCT05422183 2022-06-16
Envafolimab, Lenvatinib Combined With VP-16 in Platinum-resistant Recurrent Epithelial Ovarian Cancer
Zhongda Hospital
Phase 2 Unknown
NCT01649180 2021-08-12
PrE0801
PrECOG, LLC.
Phase 2 Terminated
NCT04760431 2021-06-02
TKIs vs. Pertuzumab in HER2+ Breast Cancer Patients With Active Brain Metastases (HER2BRAIN)
Second Affiliated Hospital, School of Medicine, Zhejiang University
Phase 2 Unknown
NCT02687425 2016-02-22
SESPI
Tongji Hospital
Phase 2 Unknown